Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06014905 · ClinicalTrials.gov registry record · Phase 1
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma
A Phase 1 study of Meningioma, sponsored by Javier Villaneuva-Meyer, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06014905: Recruiting Phase 1 study of Meningioma, sponsored by Javier Villaneuva-Meyer, MD.
NCT06014905 is a Phase 1 study of Meningioma that is actively recruiting participants, run by Javier Villaneuva-Meyer, MD. The registered enrollment target is 50 participants, below the 97-participant average among 21 other Meningioma trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06014905, a Phase 1 study of Meningioma, is actively recruiting participants, sponsored by Javier Villaneuva-Meyer, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Pilot/Phase I clinical study of hyperpolarized 13C (HP 13C) pyruvate injection that includes the acquisition of magnetic resonance (MR) data performed on participants with meningioma to evaluate metabolism and aid in the non-invasive characterization of aggressive tumor behavior
Primary Outcome
All participants who are enrolled in the study and receive any amount of hyperpolarized 13C pyruvate will be included in the primary outcome analysis. The proportion of participants who complete hyperpolarized 13C pyruvate MR imaging will be reported. If the proportion is greater than 0.7, hyperpolarized 13C MR imaging will be determined to be feasible.
Conditions Studied
Interventions
- OTHER Saline
- PROCEDURE Magnetic Resonance Image (MRI)
- DRUG Hyperpolarized carbon C 13 pyruvate
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-09-01 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 1 |
What NCT06014905 shows while recruiting
NCT06014905 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 97-participant average among 21 other Meningioma trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Meningioma appearing as the primary indexed condition, and to 3 interventions - of which Saline is the first listed.
NCT06014905 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06014905 about?
NCT06014905 is a clinical study titled "Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma". This is a Pilot/Phase I clinical study of hyperpolarized 13C (HP 13C) pyruvate injection that includes the acquisition of magnetic resonance (MR) data performed on participants with meningioma to evaluate metabolism and aid in the non-invasive characterization of aggressive tumor behavior
What is the current status of trial NCT06014905?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2023-09-01. Estimated completion is 2026-09-30.
What conditions does trial NCT06014905 study?
This clinical trial studies the following conditions: Meningioma.
What interventions are being tested in trial NCT06014905?
The interventions under investigation include: Saline (OTHER), Magnetic Resonance Image (MRI) (PROCEDURE), Hyperpolarized carbon C 13 pyruvate (DRUG).
Who is sponsoring clinical trial NCT06014905?
This trial is sponsored by Javier Villaneuva-Meyer, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06014905 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meningioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06014905's enrollment target sits among peer trials
50 10th of 21 higher than 12 of 21 other Meningioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Meningioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
RECRUITING · Phase 1
-
Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas
COMPLETED · Phase 1
-
Abemaciclib in Newly Diagnosed Meningioma Patients
RECRUITING · Phase 2
-
Evaluation of the CONVIVO System
RECRUITING · NA
-
Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI